15:08 , Nov 15, 2018 |  BioCentury  |  Politics, Policy & Law

Requiring Drug Prices in TV Ads Violates First Amendment

Drug companies, which have learned to live with advertisements calling out a litany of possible side effects for their drugs, may want to take a couple of aspirin. The recent announcement by CMS that it...
22:01 , Oct 4, 2018 |  BC Innovations  |  Tools & Techniques

Lilly: academic about manufacturing

As Eli Lilly and Co. moves toward continuous manufacturing, the pharma is deepening ties with two academic centers to meet an array of engineering challenges. Through partnerships with Carnegie Mellon University, and the U.K.’s Imperial...
18:49 , Oct 20, 2017 |  BioCentury  |  Regulation

Realities of real-world evidence

After countless conferences, white papers and speeches, stakeholders across the healthcare ecosystem are finally coming together to figure out how to extend the use of real-world evidence beyond pharmacovigilance and into drug development. The payoffs...
19:54 , Sep 1, 2017 |  BC Week In Review  |  Clinical News

Xarelto lowers CV risk, ups major bleeds in Phase III for artery disease

The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) reported full data from the Phase III COMPASS trial showing that twice-daily 2.5 mg oral Xarelto rivaroxaban (BAY 59-7939) plus once-daily 100 mg...
22:59 , Aug 28, 2017 |  BC Extra  |  Clinical News

Xarelto lowers CV risk, ups major bleeds in artery disease

The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) released full data from the Phase III COMPASS trial showing that twice-daily 2.5 mg oral Xarelto rivaroxaban plus once-daily 100 mg aspirin reduced...
14:07 , Aug 23, 2017 |  BC Innovations  |  Distillery Techniques

Assays and screens; drug properties

TECHNOLOGY: Cellular assays; toxicology A culture system for generating gut tubules could be used to screen drug compounds for adverse effects on the gut epithelial barrier. The method involves seeding human intestinal colorectal adenocarcinoma cells...
07:16 , Jul 29, 2017 |  BioCentury  |  Finance

Show us your shorts

Absent any data showing a sustained impact of manipulative short selling on biotech valuations or their ability to raise capital, it is difficult to discern what direct benefit biotech companies would gain from BIO ’s...
00:34 , Jun 30, 2017 |  BC Extra  |  Preclinical News

Hormone tied to treating preeclampsia

In a paper published in...
18:32 , Mar 31, 2017 |  BC Week In Review  |  Clinical News

Xarelto: Ph III EINSTEIN CHOICE data

The double-blind, international Phase III EINSTEIN CHOICE trial in 3,365 patients with confirmed symptomatic deep vein thrombosis (DVT) or pulmonary embolism (PE) who were initially treated with 6 or 12 months of anticoagulation therapy showed...
18:31 , Mar 31, 2017 |  BC Week In Review  |  Clinical News

Xarelto: Ph II GEMINI-ACS-1 data

The double-blind, international Phase II GEMINI-ACS-1 trial in 3,037 patients with ACS showed that twice-daily 2.5 mg oral Xarelto plus clopidogrel or Brilinta ticagrelor led to no significant difference in the rate of TIMI clinically...